



Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
(617) 252-7570

Fast Facts About Genzyme Corporation

Founded:	1981
2010 Revenues:	\$4.05 billion
2010 R&D Spending:	\$786 million
Employees Worldwide:	Approximately 10,000
Headquarters:	Cambridge, MA
Areas of Focus:	Rare Genetic Diseases, Multiple Sclerosis, Cardiovascular Disease, Endocrinology
Parent Company:	In 2011, Genzyme became a Sanofi company.

Top Products, based on FY 2010 Revenue:

<u>Product Name</u>	<u>Disease/Condition</u>	<u>Revenue 2010</u>
Cerezyme [®] (imiglucerase for injection)	Gaucher disease	\$720 million
Sevelamer (Renagel [®] and Renvela [®])	renal disease	\$698 million
Alglucosidase alfa (Myozyme [®] and Lumizyme [®])	Pompe disease	\$412 million
Synvisc [®] (hylan G-F 20)	osteoarthritis of the knee	\$393 million

Key Pipeline Products:

<u>Product Name</u>	<u>Disease/Condition</u>
alemtuzumab	multiple sclerosis
mipomersen	familial hypercholesterolemia
eliglustat tartrate	Gaucher disease type 1

International Presence:

Genzyme has nearly 65 locations in over 40 countries, including 11 manufacturing facilities; the company's products are available in nearly 100 countries.

Charitable Contributions, FY 2010:

Global product donations, \$75 million
U.S. cash contributions, \$12 million